IGFBP-2 Human ELISA

Features

• Measures total IGFBP-2 concentration in serum, plasma and in other human body fluids
• single standards with 2; 10; 20; 40 and 80 ng/ml are
• Total Incubation time only 1.75 hours
• 2 Control Sera are provided for quality control purposes according GLP
• ready-to-use Antibody Conjugate
• no sample extraction needed
• Microtiterplate seperately break apart

Research topic

Growth hormone and factor-related products, Oncology

Summary

Insulin-like growth factors (IGFs) regulate the proliferation, differentation, apoptose, cell adhesion and metabolism in various tissues and cell types. The IGF-1, which is produced mainly in liver under the influence of growth hormone (GH), regulates as hormone the linear growth of the bones and the process of sexual maturity, while IGF-2 is mainly a growth factor of fetal tissue. The biological actions of IGF over the IGF-Type-1 receptor are modulated variably through the IGF binding proteins (IGFBP-1 to-6). IGFBP-2 is, after IGFBP-3, the second most frequent IGFBP in the human blood. IGFs, especially tumor typical pro-IGF-forms and hormones regulate the expression of IGFBP-2, GH effect is thereby inhibiting. At cellular level IGFBP-2 seems to stimulate the proliferation and dissemination of solid tumors via an IGF-independent mechanism.

IGFBP-2 is a unglycosylated polypetide of 31.3 kDa, which forms binary IGF-complexes and shows no circadian rhythm in the circulation.The serum concentration of IGFBP-2 increases in fasting, after major surgery and after trauma, but the increasing of the concentration is most intensive in malignant diseases. The correlation of the IGFBP-2 level to the degree of progression is a striking feature in various tumor types as is the normalization of the IGFBP-serum levels after remission. The IGFBP-2 concentration is age-dependent in blood.